Live
FierceBiotechAmgen loses in Harbour antibody patent case, ordered to pay $20M+FierceBiotechIntellia touts ‘paradigm-shifting’ phase 3 data for one-time HAE treatmentFierceBiotechNeumora to lay off 35% of staff after navacaprant goes 0 for 3 in late-stage depression studiesEndpoints NewsNeumora drug fails two more Phase 3 trials, biotech to lay off 35% of staffClinical OMICsRewriting Cancer Care Through EpigeneticsFierceBiotechTraws defers midphase flu study after negative regulatory reviewEndpoints NewsSix leaders working on LGBTQ+ inclusion in biopharmaBioWorldEnsem Therapeutics patents new GTPase KRAS mutant inhibitorsBioWorldCaregen reports new GLP-1R agonistsBioWorldIteos Belgium discloses new PTPN1/2 inhibitorsBioWorldJiangsu Aidea Pharmaceutical identifies amide compounds for HIVBioWorldNew SOS1 inhibitors divulged in Sichuan Huiyu patent
WuXi Biologics 25 avr. 2026

WuXi Biologics Secures MFDS GMP Certification For Three Key Manufacturing Facilities - BioPharma APAC

WuXi Biologics Secures MFDS GMP Certification For Three Key Manufacturing Facilities - BioPharma APAC

Contenu indisponible. Consultez la source originale.